ArticleIrish journal of medical science2025
MiR-144-3p participates in the regulation of gestational diabetes mellitus by targeting FOXO1.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Downregulation of miR-3074-5p slows cervical cancer progression by targeting TGFBR2 expression.Irish journal of medical science · 2026Article
- miR-326 serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell viability.Irish journal of medical science · 2025Article
- Zinc as a Modulator of miRNA Signaling in Obesity.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pivotal role of microRNAs (miRNAs) in the pathogenesis of gestational diabetes mellitus (GDM) have been increasingly highlighted in recent studies.
aimsTo investigate miR-144-3p expression in patients with GDM and its potential mechanisms in GDM.
methodsAccording to the inclusion criteria, 98 pregnant women with GDM and 98 normal pregnant women were statistically selected. The levels of miR-144-3p were determined by RT-qPCR. The ROC curve was used to evaluate the diagnostic value of miR-144-3p for GDM. Pearson analysis was used to analyze the correlation. HRT-8/SVneo cells were induced by high glucose in vitro to mimic the high glucose environment of GDM. On this basis, the cell models of miR-144-3p overexpression and knockdown were established to investigate the potential mechanism of miR-144-3p in GDM.
resultsThe level of miR-144-3p in GDM group was markedly higher than that in normal pregnant women. In terms of predicting GDM, miR-144-3p demonstrated high accuracy. MiR-144-3p was positively linked to blood glucose markers in GDM. Further investigation has confirmed that miR-144-3p harbors a binding site for FOXO1 and can directly modulate its expression. Moreover, miR-144-3p targeted FOXO1 to affect the proliferation of trophoblast cells.
conclusionThe expression of miR-144-3p is elevated in pregnant women with GDM. MiR-144-3p may be involved in the regulation of GDM by targeting FOXO1.
Indexed as
Identifiers
39945941What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.